Cargando…

Enoxaparin 20 mg for thromboprophylaxis in severe renal impairment

OBJECTIVE: This study was performed to evaluate the efficacy of daily subcutaneous enoxaparin 20 mg in patients with renal failure. METHODS: This retrospective cohort study included nonsurgical patients aged ≥18 years with a creatinine clearance rate of <30 mL/minute who were prescribed enoxapari...

Descripción completa

Detalles Bibliográficos
Autores principales:	Karaoui, Lamis R., Tawil, Samah, Salameh, Pascale, Chamoun, Nibal
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2018
Materias:	Clinical Research Reports
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6384464/ https://www.ncbi.nlm.nih.gov/pubmed/30259770 http://dx.doi.org/10.1177/0300060518799896

Ejemplares similares

Evaluation of prophylactic dosages of Enoxaparin in non-surgical elderly patients with renal impairment
por: Chamoun, Nibal, et al.
Publicado: (2019)

Impact of pharmacist-conducted anticoagulation patient education and telephone follow-up on transitions of care: a randomized controlled trial
por: Karaoui, Lamis R., et al.
Publicado: (2021)

Assessing the perceptions of pharmacists working in Lebanese hospitals on the continuing education preferences
por: Iskandar, Katia, et al.
Publicado: (2018)

Outcomes of thromboprophylaxis with enoxaparin vs. unfractionated heparin in medical inpatients
por: McGarry, Lisa J, et al.
Publicado: (2006)

Value of pharmacy services upon admission to an orthopedic surgery unit
por: Ouweini, Ahmad El, et al.
Publicado: (2021)

A Prospective Observational Cohort of Clinical Outcomes in Medical Inpatients prescribed Pharmacological Thromboprophylaxis Using Different Clinical Risk Assessment Models(COMPT RAMs)
por: Chamoun, Nibal, et al.
Publicado: (2019)

Bemiparin versus enoxaparin as thromboprophylaxis following vaginal and abdominal deliveries: a prospective clinical trial
por: Alalaf, Shahla K, et al.
Publicado: (2015)

Effects of statins on clinical outcomes in hospitalized patients with community-acquired pneumonia
por: Zeenny, Rony M., et al.
Publicado: (2020)

Effectiveness, safety, and costs of thromboprophylaxis with enoxaparin or unfractionated heparin in inpatients with obesity
por: Amin, Alpesh, et al.
Publicado: (2023)

Impact of pharmacy-led medication reconciliation on admission to internal medicine service: experience in two tertiary care teaching hospitals
por: Karaoui, Lamis R., et al.
Publicado: (2019)

Postoperative decreased levels of D-dimer in patients with gynecologic cancer with enoxaparin and fondaparinux thromboprophylaxis
por: KODAMA, JUNICHI, et al.
Publicado: (2013)

Type of anaesthesia and the safety and efficacy of thromboprophylaxis with enoxaparin or dabigatran etexilate in major orthopaedic surgery: pooled analysis of three randomized controlled trials
por: Rosencher, Nadia, et al.
Publicado: (2012)

Case report: Successful thromboprophylaxis with enoxaparin in a pregnant woman with internal jugular vein agenesis
por: Di Micco, Pierpaolo, et al.
Publicado: (2022)

Pain management in hospitals: patients’ satisfaction and related barriers
por: Tawil, Samah, et al.
Publicado: (2018)

Comparison of Postoperative Bleeding in Total Hip and Knee Arthroplasty Patients Receiving Rivaroxaban, Enoxaparin, or Aspirin for Thromboprophylaxis
por: Lindquist, Desirae E., et al.
Publicado: (2018)

Comparison of efficiency and safety of rivaroxaban, apixaban and enoxaparin for thromboprophylaxis after arthroplastic surgery: a meta-analysis
por: Yu, Zhi, et al.
Publicado: (2018)

Effects of thromboprophylaxis on mesenchymal stromal cells during osteogenic differentiation: an in-vitro study comparing enoxaparin with rivaroxaban
por: Pilge, Hakan, et al.
Publicado: (2016)

Comparison of Anti-factor Xa Levels in Female and Male Patients with Obesity After Enoxaparin Application for Thromboprophylaxis
por: Wagner, Jonas, et al.
Publicado: (2022)

Comparison of the Efficacy and Safety of Rivaroxaban and Enoxaparin as Thromboprophylaxis Agents for Orthopedic Surgery—Systematic Review and Meta-Analysis
por: Rinaldi, Ikhwan, et al.
Publicado: (2022)

Antifactor Xa Levels in Critically Ill Korean Patients Receiving Enoxaparin for Thromboprophylaxis: A Prospective Observational Study
por: Lim, So Yeon, et al.
Publicado: (2013)

Nadroparine calcium or enoxaparine in acute coronary syndrome patients suffering renal insufficiency: The nadroparin versus enoxaparin (NaVe) study design
por: Gurfinkel, Enrique P, et al.
Publicado: (2004)

Standard- versus intermediate-dose enoxaparin for anti-factor Xa guided thromboprophylaxis in critically ill patients with COVID-19
por: Hamilton, David Oliver, et al.
Publicado: (2021)

Efficacy and Safety of Two Different Enoxaparin Doses for Thromboprophylaxis in Non-critically Ill Patients: A Randomized Controlled Trial
por: Alavi-Darazam, Ilad, et al.
Publicado: (2022)

Venous Thromboprophylaxis in Spine Surgery
por: Alvarado, Anthony M., et al.
Publicado: (2019)

Mandatory continuing education for pharmacists in a developing country: assessment of a three-year cycle
por: Sacre, Hala, et al.
Publicado: (2019)

Combined anticoagulant and antiplatelet therapy is associated with an improved outcome in hospitalised patients with COVID-19: a propensity matched cohort study
por: Matli, Kamal, et al.
Publicado: (2021)

A comparative study of varying doses of enoxaparin for thromboprophylaxis in critically ill patients: a double-blinded, randomised controlled trial
por: Robinson, Sian, et al.
Publicado: (2013)

Thromboprophylaxis with unilateral pneumatic device led to less edema and blood loss compared to enoxaparin after knee arthroplasty: randomized trial
por: Maradei-Pereira, João Alberto Ramos, et al.
Publicado: (2022)

Thromboprophylaxis with enoxaparin is associated with a lower death rate in patients hospitalized with SARS-CoV-2 infection. A cohort study
por: Albani, Filippo, et al.
Publicado: (2020)

Anti-factor Xa Activity Is Not Associated With Venous Thromboembolism in Critically Ill Patients Receiving Enoxaparin for Thromboprophylaxis: A Retrospective Observational Study
por: Dibiasi, Christoph, et al.
Publicado: (2022)

Postcesarean Thromboprophylaxis with Two Different Regimens of Bemiparin
por: Cruz, Milagros, et al.
Publicado: (2011)

Attitudes of Lebanese pharmacists towards online and live continuing education sessions
por: Sacre, Hala, et al.
Publicado: (2019)

Lebanese pharmacists’ confidence and self-perceptions of computer literacy: scale validation and correlates
por: Hallit, Souheil, et al.
Publicado: (2020)

American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19: July 2021 update on postdischarge thromboprophylaxis
por: Cuker, Adam, et al.
Publicado: (2022)

Dabigatran, rivaroxaban, or apixaban versus enoxaparin for thromboprophylaxis after total hip or knee replacement: systematic review, meta-analysis, and indirect treatment comparisons
por: Gómez-Outes, Antonio, et al.
Publicado: (2012)

Enoxaparin for primary thromboprophylaxis in symptomatic outpatients with COVID-19 (OVID): a randomised, open-label, parallel-group, multicentre, phase 3 trial
por: Barco, Stefano, et al.
Publicado: (2022)

Renal function and thromboprophylaxis in critically ill patients
por: Scholey, Gareth M, et al.
Publicado: (2010)

Rivaroxaban Versus Enoxaparin for Thromboprophylaxis After major Gynecological Cancer Surgery: The VALERIA Trial: Venous thromboembolism prophylAxis after gynecoLogical pElvic cancer surgery with RIvaroxaban versus enoxAparin (VALERIA trial)
por: Longo de Oliveira, André Luiz Malavasi, et al.
Publicado: (2022)

Rivaroxaban versus enoxaparin/vitamin K antagonist therapy in patients with venous thromboembolism and renal impairment
por: Bauersachs, Rupert M, et al.
Publicado: (2014)

Validation of the specialized competency framework for pharmacists in hospital settings (SCF–PHS): a cross-sectional study
por: Chamoun, Nibal, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_l250je769uhdr71qctgmj5ej9k